Pulse Biosciences, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $434.0K | $401.0K | $264.0K | $86.0K | $0 | $0 | $0 | $0 |
| Cost of Revenue | $273.0K | $370.0K | $260.0K | $279.0K | $0 | $0 | — | $0 |
| Gross Profit | $161.0K | $31.0K | $4.0K | $-193.0K | $0 | $0 | — | $0 |
| Gross Margin | 37.1% | 7.7% | 1.5% | -224.4% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $17.0M | $12.6M | $10.9M | $11.4M | $12.1M | $10.3M | $10.7M | $7.7M |
| SG&A Expense | $8.5M | $6.6M | $7.3M | $8.8M | $8.2M | $7.7M | $9.6M | $6.0M |
| Operating Income | $-25.3M | $-19.2M | $-18.3M | $-20.4M | $-20.3M | $-18.0M | $-20.3M | $-13.7M |
| Operating Margin | -5,823.0% | -4,775.6% | -6,914.0% | -23,682.6% | — | — | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | $-19.2M | $-16.8M | $87.8M | $-12.7M |
| Income Tax Expense | — | — | — | — | $0 | $0 | $0 | $0 |
| Net Income | $-24.7M | $-18.6M | $-17.4M | $-19.4M | $-19.2M | $-16.8M | $-19.4M | $-12.7M |
| Net Margin | -5,681.3% | -4,633.7% | -6,603.4% | -22,540.7% | — | — | — | — |
| EPS (Basic) | $-0.36 | $-0.27 | $-0.26 | $-0.29 | $-0.28 | $-0.25 | $-0.33 | $-0.21 |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
| Shares Outstanding (Basic) | 69.2M | 68.0M | 67.4M | 67.4M | 67.3M | 67.1M | 58.4M | 61.1M |
| Shares Outstanding (Diluted) | 69.2M | 68.0M | 67.4M | 67.4M | 67.3M | 67.1M | 58.4M | 61.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |